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Introduction : Myeloidderived suppressor cells (MDSCs) are critical players of tumor-
induced
immunosuppression in mouse models and cancer patients. They accumulate in the
spleen and cancers of tumorbearing hosts where they suppress Tcell activation,
proliferation and cytotoxic function [1]. Previous studies demonstrated that some
anticancer agents, in addition to their cytotoxic effects on tumor cells, were able to
affect MDSCs. This occurs for antimetabolites like 5fluorouracile (5FU) and
Gemcitabine (Gem) [2]. In this work, the potential activity of novel lipophilic 5FU and
Gem derivatives encapsulated into lipid nanocapsules (LNCs) to target monocytic (M-
)MDSC subset and tumor cells (pancreatic B6KPC3) was assessed. The aim was to
study the immunogenic and anticancer properties of innovative nanosystems.
Methods: Gem and 5FU were modified to obtain monolauroylderivatives (GemC12 and
5FUC12). The
derivatives were purified by chromatography on silica column and characterized by
nuclear magnetic
resonance. Blank and loadedLNCs were prepared using the phase inversion process
[3]. Physicochemical characterization (size, dispersity, zeta potential and
encapsulation efficiency) was performed. To study the in vitro induction of MMDSCs,
the immunosuppressive activity and internalization assays of GemC12loaded LNCs,
mouse bone marrow cells cultured in presence of GMCSF and IL6 were used. To
investigate the efficacy of 5FUC12loaded LNCs, B6KPC3 cells were employed. Finally,
as a preliminary
in vivo study, the biodistribution of fluorescentloaded LNCs (i.v. or s.c.) using tumor-
bearing mice (EG7OVA subcutaneous model) was evaluated.
Results: Lipophilic derivatives, 5FUC12 and GemC12, were synthetized. The yield of
the products recovered was 60% and 40% for 5FUC12 and GemC12, respectively.
Blank, 5FUC12 and GemC12loaded LNCs showed an average size of 60 nm, dispersity
index below 0.1 and neutral surface charge. The encapsulation efficiency of drugs was
close to 100%. In vitro and in vivo studies highlighted that GemC12loaded LNCs were
internalized and depleted selectively MMDSCs. Using K6PC3, we demonstrated that 5-
FUC12loaded LNCs exerted a toxic effect comparable to the commercial 5FUsolution.
In vivo studies following i.v. or s.c. administration of fluorescentloaded LNCs showed
that LNCs reached peripheral tissues. As compared with i.v., following s.c. injection,
fluorescent signal increased with time in the spleen, suggesting a slow LNCs
absorption.
Conclusions : In the present study, lipophilic 5FUC12 and GemC12loaded LNC were
obtained. GemC12
loaded LNCs were able to target MMDSCs in vivo and in vitro. Besides, 5FUC12loaded
LNCs showed
efficacy as anticancer drug in a pancreatic cell line. Further in vitro and in vivo
therapeutic evaluations would disclose the full potential of these novel LNCs.
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